Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Oncogene. 2020 Mar 2;39(17):3555–3570. doi: 10.1038/s41388-020-1235-2

Figure 1. SLC16A1 (MCT1) expression is prognostic for poor outcome in primary neuroblastoma.

Figure 1.

(A–D) Kaplan-Meier curves for event-free survival (EFS) and overall survival (OS) based on SLC16A1 or SLC16A3 mRNA expression in an expression array dataset from a prospectively accrued primary neuroblastoma cohort of 649 patients (21). Gene expression was dichotomized at the median. SLC16A1 EFS: HR = 3.33, 95% CI = 2.48–4.47, P < 0.001. SLC16A1 OS, HR = 6.23, 95% CI = 4.04–9.60, P < 0.001. SLC16A3 EFS: HR = 0.98, 95% CI = 0.75 SLC16A3–1.28, P < 0.001. SLC16A3 OS: HR = 1.04, 95% CI = 0.744–1.44, P < 0.001. (E–F) SLC16A1 mRNA expression was higher in MYCN-amplified compared to MYCN non-amplified tumors, while SLC16A3 expression was lower. ****P<0.0001.